Are valuations in the mid-cap segment now fairly priced? No. Does it mean you should avoid the segment altogether? The answer is again no. ...

As global equity markets expand, two corporate heavyweights are emerging as serious contenders to reach $1 trillion in market capitalizatio...

This JV between Narayana Health Group, health-focussed early-stage venture fund W Health Ventures and its venture studio 2070 Health, will ...

Reliance Industries Ltd, led by Mukesh Ambani, has invested USD 13 billion in acquisitions over the past five years, focusing on new energy...

Analysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which ...

The healthtech ecosystem in India has flourished since the onset of the pandemic, and several scaled healthcare startups have emerged. Gear...

Gland Pharma shares were available at a premium of Rs 20 in the grey market during the offer subscription period between Nov 9 and 11. The ...

The drugmarker will likely announce the name of anchor investors by the end of Friday.

We have zeroed in on five stocks which have seen their PE multiple soften by over 20% since December last year, making them attractive.

Exclusive interview with Sunder Genomal, Managing Director, Page Industries and Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals

An IIM- Ahmedabad alumna, Nayar founded Nykaa in 2012 after quitting as MD of Kotak Mahindra Capital Company, where she had spent 18 years.

The drugmaker sold its Rs 1,332 crore initial public offering (IPO) between December 6 and December 8, which was subscribed 4.52 times.

The startup utilises a supramolecular technology platform to design anti-cancer drugs that home into the tumor and modulate the tumor immun...

After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, t...

Aurobindo Pharma is targeting a revenue of over $3 billion (over Rs 19,800 crore) by 2017-18 and plans to expand its basket with drugs to t...

Aurobindo is targetting a revenue of over $ 3 billion by 2017-18 and plans to expand its basket with new drugs to treat cancer.

Mid-sized pharma firm Marksans Pharma has acquired UK’s leading generic drug marketing and distribution company Relonchem for Rs 100 crore.